Functional Cardiac Liabilities
The Drug Development Challenge
Identifying functional cardiac liabilities remains a critical bottleneck in preclinical safety, toxicity and efficacy testing. While many assays focus on single endpoints like beat rate or viability, they often miss subtle changes in contractile strength, timing, or rhythm that can signal early dysfunction. Such limitations reduce translational predictivity and may allow compounds with hidden cardiac risk to advance. This is particularly problematic in early-phase programs, where decisions rely heavily on accurate human-relevant data.
Our Solution
Our human iPSC-derived cardiomyocyte assay platform enables precise, mechanosensitive quantification of functional cardiac responses under acute or chronic exposure. Using FLEXcyte 96 technology, we measure contraction force (mN/mm²), contraction/relaxation kinetics and arrhythmic events in real time. These high-content readouts provide a comprehensive view of how a compound influences the contractile behavior of human cardiac cells. Our solution leverages technology applied in CiPA follow-up studies (Comprehensive in vitro Proarrhythmia Assay), ensuring scientific rigor and regulatory relevance. With customizable protocols and rapid turnaround, we deliver robust functional data tailored to both discovery and regulatory needs.
